Takeda licenses epigenetic programme from CellCentric
23 February 2010
Sukaina Virji
Please Login to read the full article.
23 February 2010
Sukaina Virji
sukaina.virji@informa.com
Takeda has licensed an epigenetic programme from UK firm
CellCentric with a primary focus on cancer. The deal, which includes an upfront payment, preclinical and clinical milestones, and royalties on any future products, could be worth more than $200 million to CellCentric over the course of the...
Please Login to read the full article.
RELATED CONTENT
NEWS
- 7th Annual Scrip Awards: Novartis, Jimenez, Burrill, Glenmark, ICON win
- Forma strikes discovery deal with Janssen in cancer metabolism, worth up to $700M
- Takeda snags Intellikine in bid to bolster oncology pipeline
- Genentech in rare deal to buy preclinical tumour metabolism programme from Forma
FEATURES
- Merck BioVentures: where biosimilars make a difference
- Chinese producers may be losing price edge to India, says Granules MD
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
